Corient Private Wealth LLC Sells 10,961 Shares of Edwards Lifesciences Corporation $EW

Corient Private Wealth LLC reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 12.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 75,913 shares of the medical research company’s stock after selling 10,961 shares during the quarter. Corient Private Wealth LLC’s holdings in Edwards Lifesciences were worth $5,937,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Norges Bank bought a new stake in Edwards Lifesciences in the second quarter valued at $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the period. Marshall Wace LLP boosted its stake in shares of Edwards Lifesciences by 127.5% during the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after purchasing an additional 3,864,908 shares in the last quarter. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 15.7% during the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after buying an additional 1,584,958 shares during the period. Finally, Holocene Advisors LP raised its stake in Edwards Lifesciences by 35.2% in the second quarter. Holocene Advisors LP now owns 4,703,977 shares of the medical research company’s stock worth $367,898,000 after buying an additional 1,223,460 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EW has been the topic of several research reports. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $90.00 to $100.00 in a research report on Thursday. Jefferies Financial Group set a $98.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 29th. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Barclays restated an “overweight” rating and set a $103.00 target price (up previously from $99.00) on shares of Edwards Lifesciences in a report on Monday, December 8th. Finally, National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $93.95.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $84.03, for a total value of $85,626.57. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,848,828.06. The trade was a 4.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. This represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 45,465 shares of company stock worth $3,804,610. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $85.66 on Friday. The firm has a market cap of $49.71 billion, a P/E ratio of 36.92, a PEG ratio of 3.81 and a beta of 0.97. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $82.53 and a 200 day moving average of $79.27.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the business posted $0.67 EPS. The company’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.